Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Benzyl N‑[(2S)‑5‑(diaminomethylamino)‑1‑[[(2S)‑4-fluoro-3-oxobutan-2-yl]amino]–1–oxopentan–2–yl]carbamate is a synthetic, experimental small molecule with a peptide-like structure. It is also known as benzoyl‐arginine‐alanine‐methyl ketone. The compound contains a fluoro-substituted methyl ketone moiety and an ornithine-derived guanidinium group, suggesting it may act as an inhibitor of serine or cysteine proteases by mimicking peptide substrates and covalently modifying the active site. There are no approved indications or clinical trials for this compound, and it is not approved by any major regulatory agency[6][5][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Benzyl N-[(2S)-5-(diaminomethylamino)-1-[[(2S)-4-fluoro-3-oxobutan-2-yl]amino]-1-oxopentan-2-yl]carbamate.